Investigational medication shows promising long-term results for reducing cholesterol

September 1, 2014 3:15 PM

16 0

Long term results are promising for the investigational monoclonal antibody alirocumab. According to the results, the medication helps to significantly reduce cholesterol in conjunction with regular statin therapy while also reducing the occurrence of cardiovascular events, according to researchers in a Hot Line session on August 31 at ESC Congress 2014.

The ODYSSEY LONG TERM TRIAL involving alirocumab is the largest Phase 3 study. The study also has the longest follow-up data for proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitors, a new class of drugs.

Read more

To category page